Among them, receptor tyrosine kinase (RTK), including EGFR, feedback activation is one of the most critical mechanisms of primary resistance to KRAS G12C inhibitor monotherapy for CRC, as was seen in BRAF inhibitor monotherapy. The gene discussed is KRAS; the disease is colorectal carcinoma.